Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 1/20 | 0.56 |
| ▸ | AXL | P30530 | 3/20 | 0.50 |
| ▸ | JAK2 | O60674 | 5/20 | 0.47 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.46 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.46 |
| ▸ | HTR2A | P28223 | 1/20 | 0.45 |
| ▸ | HTR2C | P28335 | 1/20 | 0.45 |
| ▸ | HTR2B | P41595 | 1/20 | 0.45 |
| ▸ | PDPK1 | O15530 | 3/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.42 |
| ▸ | AURKA | O14965 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29644057 | 1.00 | GSK3B (0.56) | GSK3BAXLJAK2ADORA2AADORA2B | |
| SCHEMBL29613696 | 0.84 | AXL (0.50) | GSK3BAXLJAK2ADORA2AADORA2B | |
| SCHEMBL588513 | 0.84 | AXL (0.50) | GSK3BAXLJAK2ADORA2AADORA2B | |
| Hydrochloric Acid SCHEMBL588415 | 0.82 | AXL (0.49) | GSK3BAXLJAK2ADORA2AADORA2B | |
| SCHEMBL118573 | 0.81 | JAK2 (0.64) | GSK3BAXLJAK2HTR2AHTR2C | |
| SCHEMBL12193658 | 0.79 | MKNK1 (0.61) | GSK3BAXLJAK2HTR2AHTR2C | |
| SCHEMBL29769133 | 0.79 | MAP2K4 (0.57) | JAK2ADORA2AADORA2BCYP1A2KDM4E | |
| SCHEMBL12222 | 0.79 | MAP2K4 (0.57) | JAK2ADORA2AADORA2BCYP1A2KDM4E | |
| Hydrazine SCHEMBL5316054 | 0.77 | JAK2 (0.65) | GSK3BAXLJAK2ADORA2AADORA2B | |
| SCHEMBL4222590 | 0.77 | AXL (0.55) | GSK3BAXLHTR2AHTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 132 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118027006-A | 2, 4-Diaminopyrimidine derivative and preparation method and application thereof | 温州医科大学附属第一医院 | 2024-05-14 | — | — | CN | claimed |
| CN-102658057-B | Novel polyurethane dispersant and preparation method thereof | WANG ZHIJUN | 2014-09-10 | — | — | CN | claimed |
| CN-102658057-A | Novel polyurethane dispersant and preparation method thereof | ZHIJUN WANG | 2012-09-12 | — | — | CN | claimed |
| EP-0904769-B1 | Keratin fibre dye compositions containing Indazole amine derivatives and dyeing method | OREAL (FR) | 2002-09-25 | — | — | EP | claimed |
| EP-0904769-A1 | Keratin fibre dye compositions containing Indazole amine derivatives and dyeing method | L'OREAL (FR) | 1999-03-31 | — | — | EP | claimed |
| EP-4724443-A1 | PYRAZOLO-PYRIMIDINONE COMPOUNDS FOR USE IN METHODS OF INHIBITING WEE1 A KINASE | Acrivon Therapeutics, Inc. (US) | 2026-04-15 | — | — | EP | disclosed |
| US-12338226-B2 | Substituted benzodiazoles and use thereof in therapy | THOMAS HELLEDAYS STIFTELSE FOR MEDICINSK FORSKNING (SE) | 2025-06-24 | — | — | US | disclosed |
| WO-2025129167-A1 | INHIBITORS OF THE SURFACE EXPRESSION OF THE VOLTAGE-GATED SODIUM ION CHANNEL 1.7 (NAV1.7) AND THEIR THERAPEUTIC USES | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES (US) | 2025-06-19 | — | — | WO | disclosed |
| EP-3676255-B1 | THERAPEUTIC INDAZOLES | RUTGERS THE STATE UNIV UNIV OF NEW JERSEY (US) | 2025-04-16 | — | — | EP | disclosed |
| EP-4476208-A1 | GLP-1R MODULATING COMPOUNDS | Ascletis Bioscience Co., Ltd. (CN) | 2024-12-18 | — | — | EP | disclosed |
| WO-2024254490-A1 | PYRAZOLO-PYRIMIDINONE COMPOUNDS FOR USE IN METHODS OF INHIBITING WEE1 A KINASE | ACRIVON THERAPEUTICS, INC. (US) | 2024-12-12 | — | — | WO | disclosed |
| CN-118984827-A | GLP-1R modulating compounds | 歌礼生物科技（杭州）有限公司 | 2024-11-19 | — | — | CN | disclosed |
| EP-1403255-A1 | Rho KINASE INHIBITORS | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2004-03-31 | — | — | EP | disclosed |
| US-20040014755-A1 | Rho-kinase inhibitors | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2004-01-22 | — | — | US | disclosed |
| WO-2003063794-A2 | 2,4-PYRIMIDINEDIAMINE COMPOUNDS AND THEIR USES | RIGEL PHARMACEUTICALS, INC. (US) | 2003-08-07 | — | — | WO | disclosed |
| WO-2003059913-A1 | ROH-KINASE INHIBITORS | BAYER HEALTHCARE AG (DE) | 2003-07-24 | — | — | WO | disclosed |
| EP-0904769-B1 | Keratin fibre dye compositions containing Indazole amine derivatives and dyeing method | OREAL (FR) | 2002-09-25 | — | — | EP | disclosed |
| US-6027538-A | OXIDATION DYEING OF KERATINOUS FIBERS CONTAINING AT LEAST ONE COUPLER SELECTED FROM INDAZOLEAMINE DERIVATIVES AND AT LEAST ONE OXIDATION BASE; POWERFUL, NOT VERY SELECTIVE HAIR DYES WHICH ARE CAPABLE OF GENERATING INTENSE COLOR | L'OREAL S.A. (FR) | 2000-02-22 | — | — | US | disclosed |
| EP-0904769-A1 | Keratin fibre dye compositions containing Indazole amine derivatives and dyeing method | L'OREAL (FR) | 1999-03-31 | — | — | EP | disclosed |
| WO-1994014801-A1 | HETEROCYCLIC UREA DERIVATIVES AS 5HT2C AND 5HT2B ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1994-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040014755-A1 | Rho-kinase inhibitors | CIT, ROCK1, ROCK2 | GSK3B 312/4885AXL 2691/4885JAK2 1191/4885 |
| US-12338226-B2 | Substituted benzodiazoles and use thereof in therapy | XDH, CYP11B2, CYP4X1 | GSK3B 2546/4885AXL 2740/4885JAK2 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.